𝔖 Bobbio Scriptorium
✦   LIBER   ✦

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent

✍ Scribed by Xu, Kexin (author);Wu, Zhenhua Jeremy (author);Groner, Anna C. (author);He, Housheng Hansen (author);Cai, Changmeng (author);Lis, Rosina T. (author);Wu, Xiaoqiu (author);Stack, Edward C. (author);Loda, Massimo (author);Liu, Tao (author);Xu, Han (author);Cato, Laura (author);Thornton, James E. (author);Gregory, Richard I. (author);Morrissey, Colm (author);Vessella, Robert L. (author);Montironi, Rodolfo (author);Magi-Galluzzi, Cristina (author);Kantoff, Philip W. (author);Balk, Steven P. (author);Liu, X. Shirley (author);Brown, Myles (author)

Book ID
118138394
Publisher
American Association for the Advancement of Science
Year
2012
Tongue
English
Weight
869 KB
Volume
338
Category
Article
ISSN
0036-8075

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The gene for polycomb group protein enha
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer
✍ Outi R. SaramΓ€ki; Teuvo L. J. Tammela; Paula M. Martikainen; Robert L. Vessella; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 200 KB

## Abstract Overexpression of the polycomb group protein enhancer of zeste homologue 2 (__EZH2__) has been found in several malignancies, including prostate cancer, with an aggressive phenotype. Amplification of the gene has previously been demonstrated in several malignancies, but not in prostate